Biology and treatment of ductal carcinoma in situ

References

• Ernster EL, Barclay J, Kerlikowske K, Grady D, Henderson C. Incidence of and treatment for ductal carcinoma in situ of the breast. JAMA275, 913–918 (1996).
   PubMed Web of Science ®Google Scholar
• Burstein HJ, Polyak K, Wong JS, Lester SC, Kaelin CM. Ductal carcinoma in situ of the breast. N. Engl. J. Med.350, 1430–1441 (2004).
   PubMed Web of Science ®Google Scholar
• Broders AC. Carcinoma in situ contrasted with benign proliferating epithelium. JAMA99, 1670–1674 (1932).
   Google Scholar
• Bloodgood JC. Comedo carcinoma (or comedo–adenocarcinoma) of the female breast. Presented at: American Association for Cancer Research, Toronto, Canada, 28 March 1934.
   Google Scholar
• Eusebi V, Feudale E, Foschini MP et al. Long-term follow-up of in situ carcinoma of the breast. Semin. Diagn. Pathol.11(3), 223–235 (1994).
   PubMed Web of Science ®Google Scholar
• Betsill WL, Rosen PP, Lieberman PH, Robbins GF. Long-term follow-up after treatment by biopsy alone. JAMA239, 1863–1867 (1978).
   PubMed Web of Science ®Google Scholar
• Welch HG, Black WC. Using autopsy series to estimate the disease reservoir for ductal carcinoma in situ of the breast: how much breast cancer can we find? Ann. Intern. Med.127, 1023–1028 (1997).
   PubMed Web of Science ®Google Scholar
• Collins LC, Tamimi RM, Baer HJ, Connolly JL, Colditz GA, Schnitt SJ. Outcome of patient with ductal carcinoma in situ untreated after diagnostic biopsy. Cancer103(9), 1778–1784 (2005).
   PubMed Web of Science ®Google Scholar
• Ashikari R, Huvos A, Snyder R. Prospective study of non-infiltrating carcinoma of the breast. Cancer39, 435–439 (1977).
   PubMed Web of Science ®Google Scholar
• Cataliotti L, Distante V, Ciatto S et al. Intraductal breast cancer: review of 183 consecutive cases. Eur. J. Cancer28A, 917–920 (1992).
   PubMed Web of Science ®Google Scholar
• Gallagher WJ, Koerner FC, Wood WC. Treatment of intraductal carcinoma with limited surgery: long-term follow-up. J. Clin. Oncol.7(3), 376–380 (1989).
   PubMed Web of Science ®Google Scholar
• Longnecker MP, Bernstein L, Paganini-Hill A, Enger SM, Ross RK. Risk factors for in situ breast cancer. Cancer Epidemiol. Biomarkers Prev.5, 961–965 (1996).
   PubMed Web of Science ®Google Scholar
• Claus E, Stowe M, Carter D. Breast carcinoma in situ: risk factors and screening patterns. J. Natl Cancer Inst.93(23), 1811–1817 (2001).
   PubMedGoogle Scholar
• Kerlikowske K, Barclay J, Grady D, Sickles EA, Ernster V. Comparison of risk factors for ductal carcinoma in situ and invasive breast cancer. J. Natl Cancer Inst.89(1), 76–82 (1997).
   PubMedGoogle Scholar
• Amari M, Moriya T, Ishida T et al. Loss of heterozygosity analysis of asynchronous lesions of ductal carcinoma in situ and invasive ductal carcinoma of the human breast. Jpn. J. Clin. Oncol.33, 556–562 (2003).
   PubMed Web of Science ®Google Scholar
• Hwang ES, DeVries S, Chew KL et al. Patterns of chromosomal alterations in breast ductal carcinoma in situ. Clin. Cancer Res.10, 5160–5167 (2004).
   PubMed Web of Science ®Google Scholar
• Smeds J, Wärnberg F, Norberg T, Nordgren H, Holmberg L, Bergh J. Ductal carcinoma in situ of the breast with different histopathological grades and corresponding new breast tumour events: analysis of loss of heterozygosity. Acta Oncol.44, 41–49 (2005).
   PubMed Web of Science ®Google Scholar
• Claus EB, Petruzella S, Matloff E, Carter D. Prevalence of BRCA1 and BRCA2 mutations in women diagnosed with ductal carcinoma in situ. JAMA293, 964–969 (2005).
   PubMed Web of Science ®Google Scholar
• Bellamy CO, McDonald C, Salter DM, Chetty U, Anderson T. Non-invasive ductal carcinoma of the breast: the relevance of histological categorization. Hum. Pathol.24, 16–23 (1993).
   PubMed Web of Science ®Google Scholar
• Lennington WJ, Jensen RA, Dalton LW, Page DL. Ductal carcinoma in situ of the breast. Cancer73(1), 118–124 (1994).
   PubMed Web of Science ®Google Scholar
• Susnik B, Worth A, Palcic B, Poulin N, LeRiche J. Differences in quantitative nuclear features between ductal carcinoma in situ (DCIS) with and without accompanying invasive carcinoma in the surrounding breast. Anal. Cell. Pathol.8(1), 39–52 (1995).
   PubMed Web of Science ®Google Scholar
• Silverstein MJ, Poller DN, Waisman JR et al. Prognostic classification of ductal carcinoma in situ. Lancet345, 1154–1157 (1995).
   PubMed Web of Science ®Google Scholar
• Lagios MD, Page DL. Radiation therapy for in situ or localized breast cancer, N. Engl. J. Med.328, 1577–1578 (1993).
   Google Scholar
• Silverstein MJ, Lagios MD, Craig PH et al. A prognostic index for ductal carcinoma in situ of the breast. Cancer77, 2267–2274 (1996).
   PubMed Web of Science ®Google Scholar
• Silverstein MJ, Buchanan C. Ductal carcinoma in situ: USC/Van Nuys Prognostic Index and the impact of margin status. Breast12, 457–471 (2003).
   PubMed Web of Science ®Google Scholar
• Vicini FA, Recht A. Age at diagnosis and outcome for women with ductal carcinoma in situ of the breast: a critical review of the literature. J. Clin. Oncol.20, 2736–2744 (2002).
   PubMed Web of Science ®Google Scholar
• Douglas-Jones AG, Gupta SK, Attanoos RL, Morgan JM, Mansel RE. A critical appraisal of six modern classifications of ductal carcinoma in situ of the breast (DCIS): correlation with grade of associated invasive carcinoma. Histopathology29, 397–409 (1996).
   PubMed Web of Science ®Google Scholar
• Warnberg F, Nordgren H, Bergh J, Holmberg L. Ductal carcinoma in situ of the breast from a population-defined cohort: an evaluation of new histopathologic classification systems. Eur. J. Cancer35(5), 7140–7120 (1999).
   Google Scholar
• Holland R, Peterse JL, Millis RR et al. Ductal carcinoma in situ: a proposal for a new classification. Semin. Diagn. Path.11, 167–180 (1994).
   PubMed Web of Science ®Google Scholar
• AJCC Cancer Staging Manual (5th Edition). Fleming ID (Ed.). Lippincott-Raven, PA, USA (1997).
   Google Scholar
• Silverstein MJ, Waisman JB, Gamagami P et al. Intraductal carcinoma of the breast (208 cases): clinical factors influencing treatment choice. Cancer66, 55–65 (1990).
   Web of Science ®Google Scholar
• De Mascarel I, MacGrogan G, Mathoulin-Pelissier S, Soubeyran I, Picot V, Coindre JM. Breast ductal carcinoma in situ with microinvasion. Cancer94(8), 2134–2142 (2002).
   PubMed Web of Science ®Google Scholar
• Adamovich TL, Simmons RM. Ductal carcinoma in situ with microinvasion. Am. J. Surg.186, 112–116 (2003).
   PubMed Web of Science ®Google Scholar
• Zhao YG, Xiao AZ, Park HI et al. Endometase/matrilysin-2 in human breast ductal carcinoma in situ and its inhibition by tissue inhibitors of metalloproteinases-2 and -4: a putative role in the initiation of breast cancer invasion. Cancer Res.64, 590–598 (2004).
   PubMed Web of Science ®Google Scholar
• Hildenbrand R, Arens N. Protein and mRNA expression of uPAR and PAI-1 in myoepithelial cells of early breast cancer lesions and normal breast tissue. Br. J. Cancer91, 564–571 (2004).
   PubMed Web of Science ®Google Scholar
• Yunes MJ, Neuschatz AC, Bornstein LE, Naber SP, Band V, Wazer DE. Loss of expression of the putative tumor suppressor NES1 gene in biopsy-proven ductal carcinoma in situ predicts for invasive carcinoma at definitive surgery. Int. J. Rad. Oncol. Biol. Phys.56(3), 653–657 (2003).
   PubMed Web of Science ®Google Scholar
• Bock N, Meden H, Regenbrecht M, Jubemann B, Wangenin J, Marx P. Expression of the mismatch repair protein hMSH2 in carcinoma in situ and invasive cancer of the breast. AntiCancer Res.20, 119–124 (2000).
   PubMed Web of Science ®Google Scholar
• Teo NB, Shoker BS, Jarvis C, Sloane JP, Holcombe C. Angiogenesis and invasive recurrence in ductal carcinoma in situ of the breast. Eur. J. Cancer39, 38–44 (2003).
   PubMed Web of Science ®Google Scholar
• Guidi AJ, Schnitt SJ, Fischer L et al. Vascular permeability factor (vascular endothelial growth factor) expression and angiogenesis in patients with ductal carcinoma in situ of the breast. Cancer80(10), 1943–1953 (1997).
   Google Scholar
• Rice AJ, Steward MA, Quinn CM. Thrombospondin 1 protein expression relates to good prognostic indices in ductal carcinoma in situ of the breast. J. Clin. Pathol.55, 921–925 (2002).
   PubMed Web of Science ®Google Scholar
• Wulfing P, Kersting C, Buerger H et al. Expression patterns of angiogenic and lymphangiogenic factors in ductal breast carcinoma in situ. Br. J. Cancer (92), 1720–1728 (2005).
   PubMed Web of Science ®Google Scholar
• Brown LF, Guidi AJ, Schnitt SJ et al. Vascular stroma formation in carcinoma in situ, invasive carcinoma and metastatic carcinoma of the breast. Clin. Cancer Res.5, 1041–1056 (1999).
   PubMed Web of Science ®Google Scholar
• Mommers EC, van Dienst PJ, Leonhart AM, Meijer CJ, Baak JP. Balance of cell proliferation and apoptosis in breast carcinogenesis. Breast Cancer Res. Treat.58, 163–169 (1999).
   PubMed Web of Science ®Google Scholar
• Gandhi A, Holland PA, Knox WF, Potten CS, Bundred NJ. Evidence of significant apoptosis in poorly differentiated ductal carcinoma in situ of the breast. Br. J. Cancer78(6), 788–794 (1998).
   PubMed Web of Science ®Google Scholar
• Shim JY, An HJ, Lee YH, Kim SK, Lee KP, Lee KS. Overexpression of cyclooxygenase-2 is associated with breast carcinoma and its poor prognostic factors. Mod. Pathol.16(12), 1199–1204 (2003).
   PubMed Web of Science ®Google Scholar
• Shim V, Gauthier ML, Sudilovsky D et al. Cyclooxygenase-2 expression is related to nuclear grade in ductal carcinoma in situ and is increased in its normal adjacent epithelium. Cancer Res.63, 2347–2350 (2003).
   PubMed Web of Science ®Google Scholar
• Barnes N, Haywood P, Flint P, Knox WF, Bundred NJ. Survivin expression in in situ and invasive breast cancer relates to COX-2 expression and DCIS recurrence. Br. J. Cancer94(2), 253–258 (2006).
   PubMed Web of Science ®Google Scholar
• Boland GP, Butt IS, Prasad R, Knox WF, Bundred NJ. COX-2 expression is associated with an aggressive phenotype in ductal carcinoma in situ. Br. J. Cancer90, 423–429 (2004).
   PubMed Web of Science ®Google Scholar
• Hawkins RA, Teasdale A, Ferguson WA, Going JJ. Estrogen receptor activity in intraduct and invasive breast carcinomas. Breast Cancer Res. Treat.9, 129–133 (1987).
   PubMed Web of Science ®Google Scholar
• Bur ME, Zimarowski MJ, Schnitt SJ et al. Estrogen receptor immunohistochemistry in carcinoma in situ of the breast. Cancer69, 1174–1181 (1992).
   PubMed Web of Science ®Google Scholar
• Pallis L, Wilking N, Cedermark B et al. Receptors for estrogen and progesterone in breast carcinoma in situ. AntiCancer Res.12, 2113–2115 (1992).
   PubMed Web of Science ®Google Scholar
• Poller DN, Snead DRJ, Roberts EC et al. Estrogen receptor expression in ductal carcinoma in situ of the breast: relationship to flow cytometric analysis of DNA and expression of c-erbB-2 oncoprotein. Br. J. Cancer68, 156–161 (1993).
   PubMed Web of Science ®Google Scholar
• Zafrani B, Leroyer A, Fourquet A et al. Mammographically-detected ductal in situ carcinoma of the breast analysed with a new classification. A study of 127 cases : correlation with estrogen and progesterone receptors, p53 and c-erbB-2 proteins, and proliferative activity. Semin. Diagn. Pathol.11, 208–214 (1994).
   PubMed Web of Science ®Google Scholar
• Leal CB, Schmitt FC, Bento MJ et al. Ductal carcinoma in situ of the breast. Cancer75, 2213–2231 (1995).
   Google Scholar
• Warnberg F, Nordgren H, Bergkvist L, Holmberg L. Tumour markers in breast carcinoma correlate with grade rather than invasiveness. Br. J. Cancer85, 869–874 (2001).
   PubMed Web of Science ®Google Scholar
• Maxhimer JB, Pesce CE, Stewart RA, Gattuso P, Prinz RA, Xu X. Ductal carcinoma in situ of the breast and heparanase-1 expression: molecular explanation for more aggressive subtypes. J. Am. Coll. Surg.200(3), 328–335 (2005).
   PubMed Web of Science ®Google Scholar
• van de Vijver MJ, Petersee JL, Mooi WJ et al. Neu-protein overexpression in breast cancer. N. Engl. J. Med.319, 1239–1245 (1988).
   PubMed Web of Science ®Google Scholar
• Barnes DM, Meyer JS, Gonzalez JG et al. Relationship between c-erbB-2 immunoreactivity and thymidine labelling index. Breast Cancer Res. Treat.18, 11–17 (1991).
   PubMed Web of Science ®Google Scholar
• Hoque A, Sneige N, Sahn AA et al. Her-2/neu gene amplification in ductal carcinoma in situ of the breast. Cancer Epidemiol. Biomarkers Prev.11(6), 587–590 (2002).
   PubMed Web of Science ®Google Scholar
• Bauer RL, Eckhert KH, Nemoto T. Ductal carcinoma in situ-associated nipple discharge: a clinical marker for locally extensive disease. Ann. Surg. Oncol.5, 452–455 (1998).
   PubMed Web of Science ®Google Scholar
• Wang HH, Ducatman BS, Eick D. Comparative features of ductal carcinoma in situ and infiltrating ductal carcinoma of the breast on fine-needle aspiration biopsy. Am. J. Clin. Pathol.92, 736–740 (1989).
   PubMed Web of Science ®Google Scholar
• Reis-Filho JS, Malanezi F, Amendoeira I, Albergarias A, Schmidt FC. P63 staining of myoepithelial cells in breast fine needle aspirates: a study of its role in differentiating in situ from invasive ductal carcinomas of the breast. J. Clin. Pathol.55, 936–939 (2002).
   PubMed Web of Science ®Google Scholar
• Dillon MF, Quinn CM, McDermott EW, O’Doherty A, O’Higgins N, Hill AD. Diagnostic accuracy of core biopsy for ductal carcinoma in situ and its implications for surgical practice. J. Clin. Pathol.59(7), 740–743 (2006).
   PubMed Web of Science ®Google Scholar
• Stomper PC, Connolly JL, Meyer JE, Harris JR. Clinically occult ductal carcinoma in situ detected by mammography: analysis of 100 cases with radiologic-pathologic correlation. Radiology172, 235–241 (1989).
   PubMed Web of Science ®Google Scholar
• Holland R, Hendriks JHCL, Verbeek ALM, Mravunac M, Schuurmans Stekhoven JH. Extent, distribution, and mammographic/histological correlations of breast ductal carcinoma in situ. Lancet335, 519–522 (1990).
   PubMed Web of Science ®Google Scholar
• Drew PJ, Chatterjee S, Turnbull LW et al. Dynamic contrast enhanced magnetic resonance imaging of the breast is superior to triple assessment for the preoperative detection of multifocal breast cancer. Ann. Surg. Oncol.6, 599–603 (1999).
   PubMed Web of Science ®Google Scholar
• Boetes C, Strijk SP, Holland R, Barentsz JO, van der Sluis RT, Ruiss JH. False-negative MR imaging of malignant breast tumors. Eur. Radiol.7(8), 1231–1234 (1997).
   PubMed Web of Science ®Google Scholar
• Neubauer H, Mengxia Li, Kuehne-Heid R, Schneider A, Kaiser WA. High grade and non-high grade ductal carcinoma in situ on dynamic MR mammography: characteristic findings for signal increase and morphological pattern of enhancement. Br. J. Radiol.76, 3–12 (2003).
   PubMed Web of Science ®Google Scholar
• Silverstein MJ, Barth A, Poller DN et al. Ten year results comparing mastectomy to excision and radiation therapy for ductal carcinoma in situ of the breast. Eur. J. Cancer31, 1425–1427 (1995).
   Google Scholar
• Veronesi U, Saccozzi R, Del Vecchio et al. Comparing radical mastectomy with quadrantectomy, axillary dissection and radiation therapy in patients with small cancers of the breast. N. Engl. J. Med.305, 6–11 (1981).
   PubMed Web of Science ®Google Scholar
• Fisher B, Anderson S, Redmond CK, Wolmark N, Wickerham DL, Cronin WM. Reanalysis and results after 12 years of follow-up in a randomized clinical trial comparing total mastectomy and lumpectomy with or without irradiation in the treatment of breast cancer. N. Engl. J. Med.333, 1456–1461 (1995).
   PubMed Web of Science ®Google Scholar
• Mokbel K, Choy C, Leris C et al. Predictors of positive margins after local excision of ductal carcinoma in situ. Am. J. Surg.181, 91–95 (2001).
   PubMed Web of Science ®Google Scholar
• Chan KC, Knox WF, Sinha G et al. Extent of excision margin width required in breast conserving surgery for ductal carcinoma in situ. Cancer91(1), 9–16 (2001).
   PubMed Web of Science ®Google Scholar
• Cheng L, Al-Kaisi NK, Gordon NH, Liu AY, Gebrail F, Shenk RR. Relationship between the size and margin status of ductal carcinoma in situ of the breast and residual disease. J. Natl Cancer Inst.89(18), 1356–1360 (1997).
   PubMedGoogle Scholar
• Holland PA, Gandhi A, Knox WF et al. The importance of complete excision in the prevention of local recurrence of ductal carcinoma in situ. Br. J. Cancer77(1), 110–114 (1998).
   PubMed Web of Science ®Google Scholar
• Trisal V, Qian D, Wagman LD. Axillary recurrence in DCIS: is axillary lymphadenectomy warranted? Am. Surg.70(10), 876–880 (2004).
   PubMed Web of Science ®Google Scholar
• Zavagno G, Carcoforo P, Marconato R et al. Role of axillary sentinel lymph node biopsy in patients with pure ductal carcinoma in situ of the breast. BMC Cancer5, 28 (2005).
   PubMed Web of Science ®Google Scholar
• Goyal A, Douglas-Jones A, Monypenny I, Sweetland H, Stevens G, Mansel RE. Is there a role of sentinel lymph node biopsy in ductal carcinoma in situ?: analysis of 587 cases. Breast Cancer Res. Treat.98(3), 311–314 (2006).
   PubMed Web of Science ®Google Scholar
• Lara JF, Young SM, Velilla RE, Santoro EJ, Templeton SF. The relevance of occult axillary micrometastases in ductal carcinoma in situ. A clinicopathologic study with long-term follow-up. Cancer98(10), 2105–2113 (2003).
   PubMed Web of Science ®Google Scholar
• Wong JS, Kaelin CM, Troyan SL et al. Prospective study of wide excision alone for ductal carcinoma in situ of the breast. J. Clin. Oncol.24(7), 1031–1036 (2006).
   PubMed Web of Science ®Google Scholar
• Fisher B, Dignam J, Wolmark N et al. Lumpectomy and radiation therapy for the treatment of intraductal breast cancer: findings from the National Surgical Adjuvant Breast and Bowel Project B-17. J. Clin. Oncol.16(2), 441–452 (1998).
   PubMed Web of Science ®Google Scholar
• Fisher B, Costantino J, Redmond C et al. Lumpectomy compared with lumpectomy and radiation therapy for the treatment of intraductal breast cancer. N. Engl. J. Med.328(22), 1581–1586 (2003).
   Google Scholar
• Julien J-P, Bijker N, Fentiman IS et al. Radiotherapy in breast-conserving treatment for ductal carcinoma in situ: first results of EORTC randomized Phase III trial 10853. Lancet355, 528–533 (2000).
   PubMed Web of Science ®Google Scholar
• Bijker N, Peterse JL, Duchateau L et al. Risk factors for recurrence and metastases after breast-conserving therapy for ductal carcinoma-in situ: analysis of European Organization for Research and Treatment of Cancer Trial 10853. J. Clin. Oncol.19(8), 2263–2271 (2001).
   PubMed Web of Science ®Google Scholar
• Houghton J, George WD, Cuzick J, Duggan C, Fentiman IS, Spittle M. Radiotherapy and tamoxifen in women with completely excised ductal carcinoma in situ of the breast in the UK, Australia and New Zealand: randomized controlled trial. Lancet362(9378), 95–102 (2003).
   PubMed Web of Science ®Google Scholar
• Emdin SO, Granstrand B, Ringberg A et al. Radiotherapy after sector resection for ductal carcinoma in situ of the breast. Results of a randomised trial in a population offered mammography screening. Acta Oncol.45, 536–543 (2006).
   PubMed Web of Science ®Google Scholar
• Ceilley E, Jagsi R, Goldberg S, Kachnic L, Powell S, Taghian A. The management of ductal carcinoma in situ in North America and Europe. Cancer101(9), 1958–1967 (2004).
   PubMed Web of Science ®Google Scholar
• Fisher B, Costantino J, Redmond C et al. Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomized controlled trial. Lancet353, 1993–2000 (1999).
   PubMed Web of Science ®Google Scholar
• Kestin LL, Goldstein NS, Martinez AA et al. Factors associated with local recurrence of mammographically detected ductal carcinoma in situ in patients given breast-conserving therapy. Cancer88(3), 596–607 (2000).
   PubMed Web of Science ®Google Scholar
• Boland GP, Chan KC, Knox WF, Roberts SA, Bundred NJ. Value of the Van Nuys Prognostic Index in prediction of recurrence of ductal carcinoma in situ after breast conserving surgery. Br. J. Surg.90, 426–432 (2003).
   PubMed Web of Science ®Google Scholar
• Li CI, Malone KE, Saltzman BS, Daling JR. Risk of invasive breast cancer among women diagnosed with ductal carcinoma in situ and lobular carcinoma in situ, 1988–2001. Cancer106(10), 2104–2112 (2006).
   PubMed Web of Science ®Google Scholar
• Fisher E, Dignam J, Tan-Chiu E et al. Pathologic findings from the National Surgical Adjuvant Breast Project (NSABP) eight-year update of Protocol B-17. Cancer86(3), 429–438 (1999).
   PubMed Web of Science ®Google Scholar
• Gupta SK, Douglas-Jones AG, Fenn N, Morgan JM, Mansel RE. The clinical behaviour of breast carcinoma is probably determined at the pre-invasive stage (ductal carcinoma in situ). Cancer80(9), 1740–1745 (1997).
   PubMed Web of Science ®Google Scholar
• Bijker N, Peterse JL, Duchateau L et al. Histological type and marker expression of the primary tumor compared with its local recurrence after breast conserving surgery for ductal carcinoma in situ. Br. J. Cancer84(4), 539–544 (2001).
   PubMed Web of Science ®Google Scholar
• Romero L, Ye W, Holmes D et al. Outcome after invasive recurrence in patients with ductal carcinoma in situ of the breast. Am. J. Surg.188, 371–376 (2004).
   PubMed Web of Science ®Google Scholar
• Habel LA, Dignam JJ, Land SR et al. Mammographic density and breast cancer after ductal carcinoma in situ. J. Natl Cancer Inst.96(19), 1467–1472 (2004).
   PubMed Web of Science ®Google Scholar
• Roka S, Rudas M, Taucher S et al. High nuclear grade and negative estrogen receptor are significant risk factors for recurrence in DCIS. Eur. J. Surg. Oncol.30(3), 243–247 (2004).
   PubMed Web of Science ®Google Scholar
• Cornfield DB, Palazzo JP, Schwartz GF et al. The prognostic significance of multiple morphologic features and biologic markers in ductal carcinoma in situ of the breast. Cancer100(11), 2317–2327 (2004).
   PubMed Web of Science ®Google Scholar
• Kerlikowske K, Molinari A, Cha I et al. Characteristics associated with recurrence among women with ductal carcinoma in situ treated by lumpectomy. J. Natl Cancer Inst.95(22), 1692–1702 (2003).
   PubMedGoogle Scholar
• Ringberg A, Idvall I, Ferno M et al. Ipsilateral local recurrence in relation to therapy and morphological characteristics in patients with ductal carcinoma in situ of the breast. Eur. J. Surg. Oncol.26, 444–451 (2000).
   PubMed Web of Science ®Google Scholar
• Baxter NN, Virnig BA, Durham SB, Tuttle TM. Trends in the treatment of ductal carcinoma in situ of the breast. J. Natl Cancer Inst.96(6), 443–448 (2004).
   PubMedGoogle Scholar
• Recht A, Rutgers EJ, Fentiman IS, Kurtz JM, Mansel RE, Sloane JP. The Fourth EORTC DCIS Consensus Meeting Conference Report. Eur. J. Cancer34(11), 1664–1669 (1998).
   PubMedGoogle Scholar
• Schwartz GF, Solin LJ, Olivotto IA, Ernster VL, Pressman P. The Consensus Conference on the treatment of in situ ductal carcinoma of the breast, 22–15 April 1999. Breast9, 177–186 (2000).
   PubMedGoogle Scholar
• Bijker N, Peterse JL, Fentiman IS, Julien JP, Hart AAM, Avril A. Effects of patient selection on the applicability of results from a randomized clinical trial (EORTC 10853) investigating breast-conserving therapy for DCIS. Br. J. Cancer87, 615–620 (2002).
   PubMed Web of Science ®Google Scholar
• White V, Pruden M, Giles G et al. Changes in the management of ductal carcinoma in situ before the release of clinical practice recommendations in Australia: the case in Victoria. ANZ J. Surg.76, 28–34 (2006).
   PubMed Web of Science ®Google Scholar
• Katz SJ, Lantz PM, Janz NK et al. Patterns and correlates of local therapy for women with ductal carcinoma-in-situ. J. Clin. Oncol.23(13), 3001–3007 (2005).
   PubMed Web of Science ®Google Scholar
• Khan SA, Wolfman JA, Segal L et al. Ductal lavage findings in women with known breast cancer undergoing mastectomy. J. Natl Cancer Inst.96(20), 1510–1517 (2004).
   PubMedGoogle Scholar
• Al Sarakbi W, Salhab M, Mokbel K. Does mammary ductoscopy have a role in clinical practice? Int. Semin. Surg. Oncol.3, 16 (2006).
   PubMedGoogle Scholar
• Matsunanga T, Kawakami Y, Namba K, Fujii M. Intraductal biopsy for diagnosis and treatment of intraductal lesions of the breast. Cancer101(10) 2164–2169 (2004).
   PubMed Web of Science ®Google Scholar
• Giardina C, Guerrieri AM, Ingravallo G et al. The stereotaxic core breast biopsy using the Mammotome: an alternative to intraoperative examination. Pathologica94, 182–189 (2002).
   PubMedGoogle Scholar
• Singletary SE, Atkinson EN, Hoque A et al. Phase II clinical trial of N-(4-hydroxyphenyl)retinamide and tamoxifen administration before definitive surgery for breast neoplasia. Clin. Cancer Res.8(9), 2835–2842 (2002).
   PubMed Web of Science ®Google Scholar